Pharmacogenomic Strategies and Personalized Medicine
Pharmacogenomic strategies are becoming increasingly important in new (and existing) therapeutic development. Regulatory initiatives are being drafted to ensure the adoption of respective assays and genetic information affecting patient care. The correct therapeutic, at the correct dose, for the appropriate patient.
Industry Coalitions, Pharmaceutical Companies and Health Care providers are implementing strategies, effectively creating Personalized Medicine through:
- Patient diagnosis and prognosis – using individual patient genetic determinants to help guide drug selection, treatment or dosing
- Patient population selection for therapeutic therapy - genetic stratification
- Drug discovery and development processes – genetic information and biological relevance guiding earlier, more informed decisions in drug development. Kill drugs early or help to identify the correct patient populations to increase efficacy while improving safety.
The Pharmacogenomics Centre is a key platform component of national Personalized Medicine strategies in Canada.
Broad Based ADME Genotyping Panel
Working with the Pharmacogenomics Centre, we create an innovative approach to Companion Diagnostic Assay development.
The Centre specializes in the development of industry best genotyping and genomic assays.
Designed to address the clinical research environment, the Centre is a cutting-edge GLP clinical genotyping laboratory that supports clinical trial work, and consists of two parallel components:
- A technology development platform
- A clinical operations platform.
The facility was built to address client requirements in the development of highly specific, sensitive and robust assays, for individual therapeutics.
Custom genomic assay and panel development is our specialty, with Industry leading expertise in SNP selection through final data analysis. This creates opportunities to expand and enhance existing research programs through the inclusion of genetic information at all phases of drug development.
One of the PGx Centre’s key strategies is to use diverse genomic and proteomic platforms to discover novel biomarkers that are predictive of drug efficacy and toxicity. Once validated with the assistance of the PGx Centre, these biomarkers will be readily transferable to the clinical setting for providing improved personalized care to patients and guidance to health professionals based on appropriate selection and dosing of drugs.
- Custom genomic assay and panel development
- DNA isolation; small to large scale
- SNP Genotyping; small to large scale
- GWAS studies
- Next generation sequencing and targeted clinical sequencing
- Pharmacogenomic and clinical genetic research (including statistical genetics, ethical, legal, social and pharmaco-economics issues)
- Pharmacology, and proteomics
All services are conducted under Good Laboratory Practices (GLP), using strict SOPs that ensure the generation of high quality results for clinical testing and in support of pharmaceutical trials.
International Expertise in Pharmacogenomics
Dr. Michael Phillips and colleagues are Internationally respected as both scientific pioneers, and clinical innovators in Pharmacogenomic assay development. The scientific staff and the Centre have worked with most major platform providers, in their content development programs.
About the Pharmacogenomics Centre
The Pharmacogenomics Centre, created in 2006, is a translational pharmacogenomics platform whose main objectives are to conduct pharmacogenomics research, provide pharmacogenomics services to the academic, biotechnology and pharmaceutical sectors, and integrate pharmacogenomics solutions into the healthcare system.
The Centre has brought together a multidisciplinary team of researchers with expertise in genomics, bioinformatics and clinical trial research. All the Centre’s clinical research studies are supported by the Centre’s unique facility, built to a GLP standard, which has the ability to perform pharmaceutical clinical trials and deliver clinical diagnostics.
The Centre has successfully leveraged its experience and expertise in technology development and pharmacogenomics clinical trial work to attract funding and collaborative partnerships in both the public and private sectors. It is a fully registered Canadian research institute, which affords many clients Canadian R&D tax incentives to conduct contracted R&D Pharmacogenomic services here.
The Pharmacogenomics Centre will ensure your assay or project is developed with requisite stringency to be integrated into your discovery process.
Designed for specificity, sensitivity, and reproducibility.